International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation

the GARFIELD-AF Background Atrial fibrillation (AF) is the most common cardiac arrhythmia in the world. We aimed to provide comprehensive data on international patterns of AF stroke prevention treatment. Methods Demographics, comorbidities, and stroke risk of the patients in the GARFIELD-AF (n = 51,270), ORBIT-AF I (n = 10,132), and ORBIT-AF II (n = 11,602) registries were compared (overall N = 73,004 from 35 countries). Stroke prevention therapies were assessed among patients with new-onset AF ( ≤ 6 weeks). Results Patients from GARFIELD-AF were less likely to

[1]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[2]  T. Wilke,et al.  Real life anticoagulation treatment of patients with atrial fibrillation in Germany: extent and causes of anticoagulant under-use , 2015, Journal of Thrombosis and Thrombolysis.

[3]  B. Gersh,et al.  Misperceptions of aspirin efficacy and safety may perpetuate anticoagulant underutilization in atrial fibrillation. , 2015, European heart journal.

[4]  G. Fonarow,et al.  Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registry. , 2014, American heart journal.

[5]  E. Hylek,et al.  National Assessment of Warfarin Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation , 2014, Circulation.

[6]  A. Parkhomenko,et al.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.

[7]  C. Murray,et al.  Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study , 2014, Circulation.

[8]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[9]  R. Sandhu,et al.  Risk stratification schemes, anticoagulation use and outcomes: the risk–treatment paradox in patients with newly diagnosed non-valvular atrial fibrillation , 2011, Heart.

[10]  B. Gersh,et al.  Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. , 2011, American heart journal.

[11]  G. Lip,et al.  Apixaban in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[12]  M. Aguilar,et al.  Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. , 2007, The Cochrane database of systematic reviews.

[13]  Stephen S. Cha,et al.  Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future Prevalence , 2006, Circulation.

[14]  D. Singer,et al.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. , 2001, JAMA.

[15]  Hugh Calkins,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. , 2014, Journal of the American College of Cardiology.

[16]  D. Xavier,et al.  Apixaban versus Warfarin in Patients with Atrial Fibrillation , 2012 .

[17]  G. Lip,et al.  International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). , 2012, American heart journal.

[18]  R. Troughton,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[19]  D. Parish,et al.  Obesity and the risk of new-onset atrial fibrillation. , 2005, JAMA.